Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206622 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 425
- Enrollment target
NCT00206622 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 425 participants.
The verdict
NCT00206622, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 425 participants
- Enrollment target
Study Summary
To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women
Interventions
- DRUG Climara PRO (Estradiol / Levonorgestrel transdermal)
- DRUG Menostar (Estradiol transdermal)
- DRUG Placebo transdermal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206622
The ClinicalTrials.gov registry entry for NCT00206622 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 425 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Climara PRO (Estradiol / Levonorgestrel transdermal) is the first listed.
NCT00206622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206622 about?
NCT00206622 is a clinical study titled "Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes". To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women
What is the current status of trial NCT00206622?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 425 participants. The study started on 2004-12. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00206622?
The interventions under investigation include: Climara PRO (Estradiol / Levonorgestrel transdermal) (DRUG), Menostar (Estradiol transdermal) (DRUG), Placebo transdermal (DRUG).
Who is sponsoring clinical trial NCT00206622?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.